Veterinary Medicines

Bovalto Respi Intranasal, Nasal spray, lyophilisate and solvent for suspension

Authorised
  • Bovine respiratory syncytial virus, strain BIO 24/A, Live
  • Bovine parainfluenza virus 3, strain BIO 23/A, Live
Download as PDF

Product identification

Medicine name:
Bovalto Respi Intranasal, Nasal spray, lyophilisate and solvent for suspension
BOVALTO RESPI INTRANASAL, ρινικό εκνέφωμα, λυοφιλοποιημένο υλικό και διαλύτης για εναιώρημα
Active substance:
  • Bovine respiratory syncytial virus, strain BIO 24/A, Live
  • Bovine parainfluenza virus 3, strain BIO 23/A, Live
Target species:
  • Cattle
Route of administration:
  • Nasal use

Product details

Active substance and strength:
  • Bovine respiratory syncytial virus, strain BIO 24/A, Live
    7.50
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
  • Bovine parainfluenza virus 3, strain BIO 23/A, Live
    6.00
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Nasal spray, lyophilisate and solvent for suspension
Withdrawal period by route of administration:
  • Nasal use
    • Cattle
      • Milk
        0
        hour
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AD07
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:
  • Glass Vial 1 x 5.0 Dose
  • Glass Vial 5 x 5.0 Dose
  • Glass Vial 1 x 10.0 Dose
  • Glass Vial 5 x 1.0 Dose

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 86539/28-09-2021/K-0230001
Date of authorisation status change:
Reference member state:
  • Czechia
Procedure number:
  • CZ/V/0141/001
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 11/07/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."